156 related articles for article (PubMed ID: 16377176)
1. Specific peptides for the therapeutic targeting of oncogenes.
Privé GG; Melnick A
Curr Opin Genet Dev; 2006 Feb; 16(1):71-7. PubMed ID: 16377176
[TBL] [Abstract][Full Text] [Related]
2. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
3. Design of a tumor-homing cell-penetrating peptide.
Myrberg H; Zhang L; Mäe M; Langel U
Bioconjug Chem; 2008 Jan; 19(1):70-5. PubMed ID: 18001077
[TBL] [Abstract][Full Text] [Related]
4. Current strategies for the development of peptide-based anti-cancer therapeutics.
Borghouts C; Kunz C; Groner B
J Pept Sci; 2005 Nov; 11(11):713-26. PubMed ID: 16138387
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades.
Bidwell GL; Raucher D
Expert Opin Drug Deliv; 2009 Oct; 6(10):1033-47. PubMed ID: 19637980
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial discovery of tumor targeting peptides using phage display.
Landon LA; Deutscher SL
J Cell Biochem; 2003 Oct; 90(3):509-17. PubMed ID: 14523985
[TBL] [Abstract][Full Text] [Related]
8. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides.
Raucher D; Moktan S; Massodi I; Bidwell GL
Expert Opin Drug Deliv; 2009 Oct; 6(10):1049-64. PubMed ID: 19743895
[TBL] [Abstract][Full Text] [Related]
10. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
11. Targeting Hsp90 for the treatment of cancer.
Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
[TBL] [Abstract][Full Text] [Related]
12. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
13. Designed TPR modules as novel anticancer agents.
Cortajarena AL; Yi F; Regan L
ACS Chem Biol; 2008 Mar; 3(3):161-6. PubMed ID: 18355005
[TBL] [Abstract][Full Text] [Related]
14. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
15. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.
Okarvi SM
Cancer Treat Rev; 2008 Feb; 34(1):13-26. PubMed ID: 17870245
[TBL] [Abstract][Full Text] [Related]
16. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.
Huq A; Singh B; Meeker T; Mascarenhas D
Anticancer Drugs; 2009 Jan; 20(1):21-31. PubMed ID: 19342998
[TBL] [Abstract][Full Text] [Related]
17. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
Erlichman C
Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
19. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
20. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
